NCT00308581 Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab Status COMPLETED Phase PHASE3
NCT00308438 Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008 Status COMPLETED Phase PHASE2
NCT00307931 Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab Status TERMINATED Phase PHASE3
NCT00306215 A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease Status COMPLETED Phase PHASE2
NCT00304252 Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease Status TERMINATED Phase PHASE2
NCT00300118 Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD) Status COMPLETED Phase PHASE3
NCT00294112 Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease Status COMPLETED Phase PHASE2
NCT00291668 Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease Status COMPLETED Phase PHASE2
NCT00287170 Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease Status COMPLETED Phase PHASE1/PHASE2
NCT00280956 Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease Status COMPLETED Phase PHASE4
NCT00278577 Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease Status TERMINATED Phase PHASE1
NCT00275418 Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease Status UNKNOWN Phase PHASE3
NCT00267722 Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease Status COMPLETED Phase PHASE2
NCT00267709 Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease Status COMPLETED Phase PHASE2